Research
Energy balance
More patients in the cagrilintide-semaglutide group than in the placebo group had a weight reduction of 5% or more.
Cagrilintide-semaglutide may be particularly effective for achieving clinically significant weight loss.
StrongSupportsmedium confidence
More patients in the cagrilintide-semaglutide group than in the placebo group had a weight reduction of 5% or more (P<0.001).
Why this rating
Based on the robust trial design and statistical significance.
Source
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Melanie J. Davies et al. · New England Journal of Medicine · 2025
DOI 10.1056/nejmoa2502082
rct · n=1206Cited 78×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Once-weekly cagrilintide-semaglutide (at a dose of 2.4 mg each) resulted in a significantly lower body weight than placebo in adults with obesity and type 2 diabetes.Strong
- The percentage of patients who had a glycated hemoglobin level of 6.5% or less was significantly higher in the cagrilintide-semaglutide group compared to the placebo group.Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →